Key Takeaways
- • Michael Novogratz, former Goldman Sachs partner and hedge fund manager, predicts psychedelics will become the next "short-term bubble" following cannabis, positioning the sector as an emerging investment opportunity for institutional capital.
- • Novogratz has backed Compass Pathways, a UK-based biotech developing psilocybin-derived drugs for therapeutic use, and publicly predicted the company will achieve a public listing before the end of 2020.
- • Compass Pathways has secured $32 million in Series A funding (as of October 2018) and counts prominent advisors including Tom Insel (former director of the National Institute of Mental Health) and David Nutt (former UK government drug czar), alongside investors including Peter Thiel and Moore Capital.
- • Early-stage clinical research from institutions like Johns Hopkins demonstrates therapeutic potential for psychedelic compounds across multiple indications, including depression, obesity, Alzheimer's disease, and smoking cessation, providing scientific foundation for commercial development.
- • Novogratz cited a fundamental market shift in perception, stating: "There's an awakening that these old drugs, these old plants, magic mushrooms or ayahuasca or the Iboga root from Africa have real positive medicinal qualities."
Summary
Michael Novogratz, the prominent cryptocurrency evangelist and former Goldman Sachs partner, made a bold public statement at the Context Summits conference at Miami's Fontainebleau Hotel, characterizing psychedelics as poised to replicate the investment trajectory and volatility witnessed in cannabis markets. Novogratz stated he is "positive this will be the next short-term bubble because it's such a positive story," reflecting his conviction that the sector will attract significant capital flows despite inherent speculation.
The investor has substantiated his thesis through direct investment in Compass Pathways, a UK-based biotechnology firm focused on clinical development and commercialization of psilocybin-based therapeutics. Novogratz publicly predicted that Compass Pathways will complete an initial public offering before year-end 2020. A Compass Pathways spokesperson declined to confirm the timeline, stating the company is "always looking at options to ensure continued growth and funding" but does not comment on "speculation." The company had raised $32 million in Series A funding as of October 2018, according to Crunchbase data.
Compass Pathways has assembled institutional credibility through its advisory board, which includes Tom Insel, the former director of the National Institute of Mental Health, and David Nutt, former UK government drug czar. The company's investor syndicate extends beyond Novogratz to include prominent venture and hedge fund figures including Peter Thiel and Moore Capital, signaling broad institutional conviction in the therapeutic opportunity.
The scientific rationale supporting Novogratz's investment thesis derives from emerging clinical research. Johns Hopkins and other top-tier institutions have established structured research programs examining psilocybin, MDMA, ketamine, and related compounds for therapeutic applications spanning depression, obesity, Alzheimer's disease, and smoking cessation. While the clinical evidence base remains early-stage, the institutional academic foundation provides regulatory and market credibility necessary for commercial drug development pathways.
Novogratz's characterization of psychedelics as an awakening to "real positive medicinal qualities" of historically stigmatized compounds reflects a broader capital market thesis: the convergence of scientific validation, regulatory scrutiny shifts, and investor appetite for alternative medicine creates a market window for early-stage commercial exploitation, analogous to cannabis market dynamics but potentially spanning broader therapeutic indications.
The investor has substantiated his thesis through direct investment in Compass Pathways, a UK-based biotechnology firm focused on clinical development and commercialization of psilocybin-based therapeutics. Novogratz publicly predicted that Compass Pathways will complete an initial public offering before year-end 2020. A Compass Pathways spokesperson declined to confirm the timeline, stating the company is "always looking at options to ensure continued growth and funding" but does not comment on "speculation." The company had raised $32 million in Series A funding as of October 2018, according to Crunchbase data.
Compass Pathways has assembled institutional credibility through its advisory board, which includes Tom Insel, the former director of the National Institute of Mental Health, and David Nutt, former UK government drug czar. The company's investor syndicate extends beyond Novogratz to include prominent venture and hedge fund figures including Peter Thiel and Moore Capital, signaling broad institutional conviction in the therapeutic opportunity.
The scientific rationale supporting Novogratz's investment thesis derives from emerging clinical research. Johns Hopkins and other top-tier institutions have established structured research programs examining psilocybin, MDMA, ketamine, and related compounds for therapeutic applications spanning depression, obesity, Alzheimer's disease, and smoking cessation. While the clinical evidence base remains early-stage, the institutional academic foundation provides regulatory and market credibility necessary for commercial drug development pathways.
Novogratz's characterization of psychedelics as an awakening to "real positive medicinal qualities" of historically stigmatized compounds reflects a broader capital market thesis: the convergence of scientific validation, regulatory scrutiny shifts, and investor appetite for alternative medicine creates a market window for early-stage commercial exploitation, analogous to cannabis market dynamics but potentially spanning broader therapeutic indications.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.